Bausch Health Canadian Unit Adds PrOKEDI to Quebec Drug List

Bausch Health's Canadian subsidiary has landed a key win for its PrOKEDI drug by getting select dosages listed on the RAMQ formulary — Quebec's government-run drug reimbursement list. That's a meaningful commercial milestone for a product trying to gain traction in Canada's tightly regulated provincial health system.

Getting onto the RAMQ list isn't just a checkbox. It means Quebec patients can now access PrOKEDI with provincial insurance coverage, which dramatically lowers the barrier to prescriptions. Without formulary status, even an approved drug can sit on pharmacy shelves collecting dust because patients can't afford it out of pocket.

Read more Apple Accuses Ex-Engineer of Stealing Secrets for OpenAI →

For Bausch Health as a company, this kind of reimbursement win matters beyond Canada. BHC is still navigating a complex financial structure tied to its planned separation of Bausch + Lomb, and every revenue-generating development for its pharmaceutical segment helps the broader turnaround story. Incremental formulary listings in major provinces can quietly move the revenue needle over time.

If you're watching BHC as a trade, reimbursement catalysts like this one tend to be underfollowed by retail investors — but they're exactly the kind of operational progress institutional holders track closely. It won't spike the stock overnight, but it's a building block. Keep it on your radar as more provincial listings could follow.

Continue reading at Yahoo Finance